{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:22:06Z","timestamp":1787862126795,"version":"build-2784847793"},"reference-count":88,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:34:41Z","timestamp":1784180081000},"page":"585-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-9858","authenticated-orcid":false,"given":"Molly","family":"Gilligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0897-3790","authenticated-orcid":false,"given":"Alexandra","family":"Gomez-Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.07.006_bib0001","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","article-title":"History of hematopoietic cell transplantation: challenges and progress","volume":"105","author":"Granot","year":"2020","journal-title":"Haematologica."},{"issue":"8","key":"10.1016\/j.clml.2026.07.006_bib0002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther."},{"issue":"12","key":"10.1016\/j.clml.2026.07.006_bib0003","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.clml.2026.07.006_bib0004","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2025.07.004","article-title":"Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR","volume":"31","author":"Jimenez Jimenez","year":"2025","journal-title":"Transplant Cell Ther."},{"issue":"17","key":"10.1016\/j.clml.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2025030823","article-title":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide","volume":"147","author":"Shaffer","year":"2026","journal-title":"Blood."},{"issue":"28","key":"10.1016\/j.clml.2026.07.006_bib0006","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol."},{"issue":"31","key":"10.1016\/j.clml.2026.07.006_bib0007","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO-25-00206","article-title":"Primary results from BMT CTN 1702: clinical transplant-related long-term outcomes of alternative donor allogeneic transplantation (CTRL-ALT-D)","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jtct.2025.11.010","article-title":"Access to allogeneic cell transplantation based on donor search prognosis: BMT CTN 1702 trial","volume":"32","author":"Dehn","year":"2026","journal-title":"Transplant Cell Ther."},{"issue":"25","key":"10.1016\/j.clml.2026.07.006_bib0009","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.clml.2026.07.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.10839","article-title":"Hematopoietic cell transplant access and patient diversity","volume":"9","author":"Cusatis","year":"2026","journal-title":"JAMA Netw Open."},{"issue":"15","key":"10.1016\/j.clml.2026.07.006_bib0011","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/bloodadvances.2025016236","article-title":"Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis","volume":"9","author":"Aljawai","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.clml.2026.07.006_bib0012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/bloodadvances.2025017194","article-title":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide","volume":"10","author":"Modi","year":"2026","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.clml.2026.07.006_bib0013","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41375-026-02903-8","article-title":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age","volume":"40","author":"Mehta","year":"2026","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.clml.2026.07.006_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2025.4551","article-title":"Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis","volume":"12","author":"Mehta","year":"2025","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.clml.2026.07.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.08.011","article-title":"The impact of isolated HLA-DQB1 mismatch and donor age in unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"31","author":"Mehta","year":"2025","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2026.05.026","article-title":"PTCy-based versus ATG-based GVHD prophylaxis in mismatched unrelated donor HCT: a secondary analysis of CIBMTR data","author":"Rodriguez-Rodriguez","year":"2026","journal-title":"Transplant Cell Ther."},{"issue":"12","key":"10.1016\/j.clml.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.clml.2026.07.006_bib0018","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.24.00921","article-title":"Improved patient-reported outcomes with post-transplant cyclophosphamide: a quality-of-life evaluation and 2-year outcomes of BMT CTN 1703","volume":"43","author":"Holtan","year":"2025","journal-title":"J Clin Oncol."},{"issue":"14","key":"10.1016\/j.clml.2026.07.006_bib0019","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","article-title":"Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703","volume":"9","author":"Abedin","year":"2025","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.clml.2026.07.006_bib0020","article-title":"Superior chronic graft-versus-host disease-free survival with post-transplant cyclophosphamide relative to tacrolimus\/methotrexate in myeloablative HLA-matched allogeneic hematopoietic cell transplantation","volume":"32","author":"Molina","year":"2026","journal-title":"Transplant Cell Ther."},{"issue":"13","key":"10.1016\/j.clml.2026.07.006_bib0021","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2025015793","article-title":"Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704","volume":"9","author":"Sorror","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2026.07.006_bib0022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.transproceed.2025.12.008","article-title":"Single center retrospective comparison of post-transplant cyclophosphamide and standard graft-versus-host disease prophylaxis in matched donor allogeneic transplantation","volume":"58","author":"Kim","year":"2026","journal-title":"Transplant Proc."},{"key":"10.1016\/j.clml.2026.07.006_bib0023","article-title":"Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant","author":"Siegel","year":"2025","journal-title":"medRxiv."},{"issue":"S3","key":"10.1016\/j.clml.2026.07.006_bib0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.27597","article-title":"Update in GVHD prophylaxis: novel pharmacologic and graft manipulation strategies","volume":"100","author":"Hexner","year":"2025","journal-title":"Am J Hematol."},{"key":"10.1016\/j.clml.2026.07.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102662","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies","volume":"97","author":"Fuji","year":"2025","journal-title":"Curr Opin Immunol."},{"issue":"4","key":"10.1016\/j.clml.2026.07.006_bib0026","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41409-025-02514-4","article-title":"The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide","volume":"60","author":"Spyridonidis","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.clml.2026.07.006_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtct.2023.12.001","article-title":"International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update","volume":"30","author":"Rotz","year":"2024","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"10.1016\/j.clml.2026.07.006_bib0028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13052","article-title":"Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation","volume":"100","author":"Schneidewind","year":"2018","journal-title":"Eur J Haematol."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0029","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.14027","article-title":"Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women","volume":"111","author":"Lee","year":"2023","journal-title":"Eur J Haematol."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jtct.2025.11.034","article-title":"Low-dose post-transplant cyclophosphamide in haploidentical stem cell transplantation: a systematic review","volume":"32","author":"Shafqat","year":"2026","journal-title":"Transplant Cell Ther."},{"issue":"10","key":"10.1016\/j.clml.2026.07.006_bib0031","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0032","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"14","key":"10.1016\/j.clml.2026.07.006_bib0033","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers16142567","article-title":"Reduced dose of post-transplant cyclophosphamide with Tacrolimus for the prevention of graft-versus-host disease in HLA-matched donor peripheral blood stem cell transplants: a prospective pilot study","volume":"16","author":"Ju\u00e1rez","year":"2024","journal-title":"Cancers (Basel)."},{"issue":"2","key":"10.1016\/j.clml.2026.07.006_bib0034","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol."},{"issue":"11","key":"10.1016\/j.clml.2026.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","article-title":"Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0036","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2024","journal-title":"Br J Haematol."},{"issue":"4","key":"10.1016\/j.clml.2026.07.006_bib0037","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ejh.70010","article-title":"Standard versus reduced-doses of post-transplant cyclophosphamide in HLA matched (10\/10) peripheral blood stem cell transplantation","volume":"115","author":"Redondo","year":"2025","journal-title":"Eur J Haematol."},{"issue":"1","key":"10.1016\/j.clml.2026.07.006_bib0038","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41409-025-02736-6","article-title":"Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity","volume":"61","author":"Lazana","year":"2026","journal-title":"Bone Marrow Transplant."},{"issue":"19","key":"10.1016\/j.clml.2026.07.006_bib0039","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFN\u03b3R signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"Choi","year":"2012","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.clml.2026.07.006_bib0040","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.clml.2026.07.006_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1304065","article-title":"Janus kinase inhibition in the treatment and prevention of graft-versus-host disease","volume":"15","author":"De Togni","year":"2024","journal-title":"Front Immunol."},{"issue":"20","key":"10.1016\/j.clml.2026.07.006_bib0042","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.clml.2026.07.006_bib0043","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease (REACH2)","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0044","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease (REACH3)","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1016\/j.clml.2026.07.006_bib0045","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/JCO-24-02477","article-title":"Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study","volume":"43","author":"Zeiser","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clml.2026.07.006_bib0046","series-title":"NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Cell Transplantation","year":"2026"},{"key":"10.1016\/j.clml.2026.07.006_bib0047","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-024-01987-x","article-title":"Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial","volume":"9","author":"Dou","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0048","article-title":"Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in haploidentical peripheral blood stem cell transplantation recipients","volume":"27","author":"Hou","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0049","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41409-026-02814-3","article-title":"Early safety of Ruxolitinib as part of GVHD prophylaxis in mismatched unrelated donor HCT","volume":"61","author":"Scarpetti","year":"2026","journal-title":"Bone Marrow Transplant."},{"issue":"20","key":"10.1016\/j.clml.2026.07.006_bib0050","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.2024028005","article-title":"Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT","volume":"145","author":"DeFilipp","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.clml.2026.07.006_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2026.04.042","article-title":"A randomized, multicenter Phase II trial to compare prophylaxis of graft-versus-host disease with Tacrolimus and mycophenolate Mofetil versus Ruxolitinib after post-transplant cyclophosphamide","author":"Moiseev","year":"2026","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0052","article-title":"Efficacy and safety of Ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"12","author":"Xie","year":"2025","journal-title":"Front Med (Lausanne)."},{"issue":"26","key":"10.1016\/j.clml.2026.07.006_bib0053","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1016\/j.clml.2026.07.006_bib0054","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2017-11-785865","article-title":"Immune regulatory cell infusion for graft-versus-host disease prevention and therapy","volume":"131","author":"Blazar","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.clml.2026.07.006_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926550","article-title":"Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease","volume":"13","author":"Hippen","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.clml.2026.07.006_bib0056","article-title":"Regulatory T cell approaches for GVHD prevention","volume":"98","author":"Bader","year":"2025","journal-title":"Curr Opin Immunol."},{"issue":"18","key":"10.1016\/j.clml.2026.07.006_bib0057","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.2024026446","article-title":"Donor regulatory T-cell therapy to prevent graft-versus-host disease","volume":"145","author":"Meyer","year":"2025","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.clml.2026.07.006_bib0058","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.2025031313","article-title":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial","volume":"147","author":"Meyer","year":"2026","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.clml.2026.07.006_bib0059","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.clml.2026.07.006_bib0060","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1172\/JCI76031","article-title":"Selective treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease","volume":"125","author":"Bolton","year":"2015","journal-title":"J Clin Invest."},{"issue":"5","key":"10.1016\/j.clml.2026.07.006_bib0061","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/bloodadvances.2023011625","article-title":"Single-center randomized trial of T-reg graft alone vs T-reg graft plus Tacrolimus for the prevention of acute GVHD","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv."},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.07.006_bib0062","doi-asserted-by":"crossref","first-page":"6552","DOI":"10.1200\/JCO.2024.42.16_suppl.6552","article-title":"Treatment of acute myeloid leukemia with Orca-T","volume":"42","author":"Pantin","year":"2024","journal-title":"J Clin Oncol."},{"issue":"21","key":"10.1016\/j.clml.2026.07.006_bib0063","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood.2025031545","article-title":"Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after orca-T immunotherapy","volume":"147","author":"Bader","year":"2026","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.clml.2026.07.006_bib0064","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/eji.201847935","article-title":"Helios+ and Helios- treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires","volume":"49","author":"Thornton","year":"2019","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.clml.2026.07.006_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1114780","article-title":"Co-expression of Foxp3 and Helios facilitates the identification of human T regulatory cells in health and disease","volume":"14","author":"Morina","year":"2023","journal-title":"Front Immunol."},{"issue":"17","key":"10.1016\/j.clml.2026.07.006_bib0066","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.2025029584","article-title":"RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT","volume":"146","author":"DeFilipp","year":"2025","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.clml.2026.07.006_bib0067","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/bloodadvances.2025017996","article-title":"Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease","volume":"10","author":"Soares","year":"2026","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.clml.2026.07.006_bib0068","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.ymthe.2022.02.025","article-title":"Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD","volume":"30","author":"Landwehr-Kenzel","year":"2022","journal-title":"Mol Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716629","article-title":"Cyclosporine A but not corticosteroids support efficacy of ex vivo expanded, adoptively transferred Human tregs in GvHD","volume":"12","author":"Landwehr-Kenzel","year":"2021","journal-title":"Front Immunol."},{"issue":"21","key":"10.1016\/j.clml.2026.07.006_bib0070","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease","volume":"6","author":"Whangbo","year":"2022","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.clml.2026.07.006_bib0071","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","article-title":"Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease","volume":"7","author":"Wobma","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2026.07.006_bib0072","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41409-025-02553-x","article-title":"Regulatory T cell therapy for graft-versus-host disease","volume":"60","author":"Lysandrou","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clml.2026.07.006_bib0073","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jtct.2025.12.991","article-title":"Tregs in allogeneic hematopoietic stem cell transplantation: suppressing graft-versus-host disease while preserving graft-versus-leukemia","volume":"32","author":"Nekouei","year":"2026","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0074","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1016\/S2152-2650(23)01528-8","article-title":"CT-632 orca-Q demonstrates favorable graft-versus-host disease (GvHD) and relapse-free survival with haploidentical donors without post-transplant cyclophosphamide","volume":"23","author":"Srour","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.clml.2026.07.006_bib0075","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.clml.2026.07.006_bib0076","article-title":"Tyrosine kinase inhibitor maintenance therapy after stem cell transplantation for FLT3-mutated acute myeloid leukemia","volume":"4","author":"Chen","year":"2025","journal-title":"Cochrane Database Syst Rev."},{"issue":"26","key":"10.1016\/j.clml.2026.07.006_bib0077","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.clml.2026.07.006_bib0078","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, Multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clml.2026.07.006_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haematopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, Multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"issue":"15","key":"10.1016\/j.clml.2026.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1016\/j.clml.2026.07.006_bib0081","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.clml.2026.07.006_bib0082","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","article-title":"Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Levis","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2026.07.006_bib0083","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol."},{"issue":"1","key":"10.1016\/j.clml.2026.07.006_bib0084","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12916-026-04744-9","article-title":"Day\u2009+\u200930 detection of minimal residual FLT3-ITD by high-sensitivity PCR-NGS predicts relapse risk and guides post-transplant maintenance in AML","volume":"24","author":"Jiang","year":"2026","journal-title":"BMC Med."},{"key":"10.1016\/j.clml.2026.07.006_bib0085","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.300176","article-title":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting Sorafenib","author":"Massoud","year":"2026","journal-title":"Haematologica."},{"issue":"14","key":"10.1016\/j.clml.2026.07.006_bib0086","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/10428194.2025.2561737","article-title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data","volume":"66","author":"Kennedy","year":"2025","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"10.1016\/j.clml.2026.07.006_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2026.03.042","article-title":"Maintenance treatment with Gilteritinib suppresses post-transplant relapse in relapsed\/refractory FLT3-mutated acute myeloid leukemia","volume":"32","author":"Arai","year":"2026","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.clml.2026.07.006_bib0088","series-title":"NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia","year":"2026"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:47:40Z","timestamp":1787860060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026002119"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}